- Home
- FLO vs CPRX Comparison
FLO vs CPRX Comparison
Compare FLO & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLO
- CPRX
- Stock Information
- Founded
- FLO 1919
- CPRX 2002
- Country
- FLO United States
- CPRX United States
- Employees
- FLO N/A
- CPRX N/A
- Industry
- FLO Packaged Foods
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- FLO Consumer Staples
- CPRX Health Care
- Exchange
- FLO Nasdaq
- CPRX Nasdaq
- Market Cap
- FLO 3.2B
- CPRX 2.6B
- IPO Year
- FLO N/A
- CPRX 2006
- Fundamental
- Price
- FLO $13.30
- CPRX $20.40
- Analyst Decision
- FLO Hold
- CPRX Strong Buy
- Analyst Count
- FLO 4
- CPRX 5
- Target Price
- FLO $16.50
- CPRX $33.20
- AVG Volume (30 Days)
- FLO 4.2M
- CPRX 1.5M
- Earning Date
- FLO 11-07-2025
- CPRX 11-05-2025
- Dividend Yield
- FLO 7.44%
- CPRX N/A
- EPS Growth
- FLO 71.08
- CPRX 183.96
- EPS
- FLO 1.04
- CPRX 1.65
- Revenue
- FLO $5,098,751,000.00
- CPRX $558,499,000.00
- Revenue This Year
- FLO $4.22
- CPRX $16.51
- Revenue Next Year
- FLO $0.08
- CPRX $9.58
- P/E Ratio
- FLO $12.79
- CPRX $12.31
- Revenue Growth
- FLO N/A
- CPRX 28.55
- 52 Week Low
- FLO $13.19
- CPRX $19.15
- 52 Week High
- FLO $23.87
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- FLO 26.25
- CPRX 51.31
- Support Level
- FLO $14.42
- CPRX $19.66
- Resistance Level
- FLO $13.79
- CPRX $20.42
- Average True Range (ATR)
- FLO 0.35
- CPRX 0.67
- MACD
- FLO -0.12
- CPRX 0.06
- Stochastic Oscillator
- FLO 5.64
- CPRX 60.89
About FLO Flowers Foods Inc.
Flowers Foods Inc is an American company producing bakery food for retail and foodservice across the United States. The product portfolio includes fresh breads, buns, rolls, snack cakes, and tortillas. The company distributes to supermarkets, convenience stores, and restaurants. The key brands are Nature's Own, Wonder, Tastykake, Canyon Bakehouse, DKB.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).